• Thomas Eschenhagen
  • Hasso Scholz


Hauptgruppen der Calciumantagonisten sind die Dihydropyridine und die relativ stärker kardiodepressiv wirkenden Substanzen Verapamil und Diltiazem.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP et al for the African American Study of Kidney Disease and Hypertension (AASK) Study Group (2001): Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 285:2719–2728.PubMedCrossRefGoogle Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (1997): Calciumantagonisten vom 1,4-Dihydropyridin-Typ. Dtsch Ärztebl 22: C-1122–C-1123.Google Scholar
  3. Blood Pressure Lowering Treatment Trialists’ Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964.CrossRefGoogle Scholar
  4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al and the National High Blood Pressure Education Program Coordinating Committee (2003): The seventh report on the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289: 2560–2572.PubMedCrossRefGoogle Scholar
  5. Cohn JN, Ziesche SM, Loss LE, Anderson GF, V-HeFT Study Group (1995): Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: Results of V-HeFT VIII. Circulation 92:1–143.CrossRefGoogle Scholar
  6. European Society of Cardiology (1997): Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 18: 394–413.CrossRefGoogle Scholar
  7. Furberg C, Psaty BM, Meyer JS (1995): Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326–1331.PubMedCrossRefGoogle Scholar
  8. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA (1999): Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 281:1927–1936.PubMedCrossRefGoogle Scholar
  9. Jørgensen B, Simonsen S, Endresen K, Forfang K, Vatne K, Hansen J et al (2000): Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 35: 592–599.PubMedCrossRefGoogle Scholar
  10. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Leiws JB et al (2001): Renopro-tective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–60.PubMedCrossRefGoogle Scholar
  11. Lüscher TF, Wenzel RR, Noll G (1996): Calciumantagonisten in der Kontroverse: Gibt es eine rationale Differentialtherapie? Dtsch Med Wochenschr 121:532–538.PubMedCrossRefGoogle Scholar
  12. North of England Stable Angina Guideline Development Group (1996): North of England evidence based guidelines development project. BMJ 312: 827–832.CrossRefGoogle Scholar
  13. Packer M (1989): Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 320:709–718.PubMedCrossRefGoogle Scholar
  14. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE et al (1996): Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335:1107–1114.PubMedCrossRefGoogle Scholar
  15. Pahor M, Psaty BM, Furberg CD (1998): Treatment of hypertensive patients with diabetes. Lancet 351:689–690.PubMedCrossRefGoogle Scholar
  16. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD (2000): Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 356:1949–1954.PubMedCrossRefGoogle Scholar
  17. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini J, Miller ME, Riley W for the PREVENT Investigators (2000): Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102:1503–1510.PubMedCrossRefGoogle Scholar
  18. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE et al (1995): The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274: 620–625.PubMedCrossRefGoogle Scholar
  19. Scholz H (1987): Wechselwirkungen zwischen Beta-Rezeptorenblockern und Anti-arrhythmika. In: Grosdanoff P et al (Hrsg): Beta-Rezeptoren und Beta-Rezepto-renblocker, Walter de Gruyter & Co, Berlin New York: S. 255–271.Google Scholar
  20. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG et al (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.PubMedCrossRefGoogle Scholar
  21. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F (1998): Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NDDM. Diabetes Care 21: 597–603.PubMedCrossRefGoogle Scholar
  22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.Google Scholar
  23. The Defiant-II Research Group (1997): Doppler flow and echocardiography in functional cardiac insufficiency: Assessment of nisoldipine therapy. Results of the DEFIANT-II study. Eur Heart J 18: 31–40.CrossRefGoogle Scholar
  24. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thjs L, Antikainen R et al (1999): Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340: 677–684.PubMedCrossRefGoogle Scholar
  25. Viberti G, Wheeldon NM for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators (2002): Microalbuminuria reduction with valsartan in patients with typ 2 diabetes mellitus. Circulation 106: 672–678.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Thomas Eschenhagen
    • 1
  • Hasso Scholz
    • 1
  1. 1.Institut für Experimentelle und Klinische PharmakologieUniversitäts-Krankenhaus EppendorfHambury

Personalised recommendations